Researchers reviewed hundreds of HPV vaccine studies. Here’s what they found
Drawing on more than 20 years of data, an independent review found strong evidence that HPV vaccines safely prevent cervical cancer.
- 8 May 2026
- 4 min read
- by Linda Geddes
At a glance
- Researchers at the Vaccine Integrity Project analysed hundreds of studies published over more than two decades to reassess the safety and effectiveness of HPV vaccines and examine growing evidence that fewer doses may still provide strong protection.
- The analysis reinforced longstanding evidence that HPV vaccines are highly safe and effective at preventing persistent HPV infection, pre-cancerous cervical changes and cervical cancer, while finding no credible link to serious long-term health risks.
- The findings also suggested that a single vaccine dose may offer protection comparable to traditional multi-dose schedules for key outcomes in women.
More than 20 years after the first HPV vaccines were introduced, a sweeping review is adding fresh weight to one of public health’s greatest success stories: the prevention of one of the leading causes of cancer deaths in women
The independent analysis by the Vaccine Integrity Project – an initiative of the University of Minnesota’s Center for Infectious Disease Research and Policy – reviewed decades of evidence from around the world, including 121 studies published between September 2024 and January 2026.
It concluded that HPV vaccines are safe and highly effective at preventing cervical cancer, pre-cancers and persistent HPV infection, with emerging evidence also supporting protection against other HPV-related cancers and pre-cancers.
It also added weight to mounting evidence that a single vaccine dose may provide comparable protection to traditional two- and three-dose regimens against persistent HPV infection and cervical pre-cancers.
“This review reinforces what decades of research on HPV vaccination have shown: that HPV vaccines are extremely safe and highly effective at preventing one of the leading causes of cancer deaths in women globally,” said Emily Kobayashi, Director of Vaccine Programmes at Gavi, the Vaccine Alliance.
“Countries who have introduced the vaccine with Gavi support in recent years can anticipate dramatic reductions in HPV, pre-cancer and cancers if they sustain their commitment to the programmes.”
Why did researchers review HPV vaccine data?
First approved in 2006, HPV vaccines are now used by more than 128 countries worldwide as a key tool for preventing cervical cancer.
Increasingly, real-world data from countries that adopted them early on shows a dramatic decline in rates of cervical disease.
Meanwhile, researchers have continued to study the best way to deliver these vaccines, including whether a single dose is truly enough to provide durable protection against HPV and the diseases it causes.
“As medical societies determine vaccine recommendations, this review provides the most up-to-date evaluation of the evidence supporting the safety and effectiveness of the HPV vaccine,” said CIDRAP’s Research Director Dr Angela Ulrich, who led the review.
The researchers combined data from 121 new peer-reviewed studies published between September 2024 and January 2026 examining HPV vaccine safety, effectiveness and how well the vaccines stimulate immune protection, along with 153 studies included in two major 2025 reviews by considered by recent reviews by the Cochrane Collaboration, an independent international network that examines medical evidence.
The analysis focused on HPV vaccines that are currently or were previously approved for use in the US, including Cervarix and Gardasil, which are widely used in Gavi-supported vaccination programmes in lower-income countries.
If you're interested in articles about the HPV vaccine, read next:
What does the science say about HPV vaccines?
The review found that HPV vaccines remain highly safe and effective at preventing persistent HPV infection, pre-cancerous cervical changes and cervical cancer.
People who received the vaccine were about 65% less likely to develop cervical cancer, with even greater protection seen among those vaccinated at age 16 or younger.
It found no credible evidence linking vaccination to serious adverse events, including infertility, pregnancy complications, neurological conditions or other long-term health risks, reinforcing the strong safety record established in earlier large-scale studies.
Importantly, it also found growing evidence that a single vaccine dose may provide comparable protection to traditional multi-dose schedules, with no meaningful differences in safety, pregnancy outcomes or protection against persistent HPV infection over five years of follow-up.
However, the researchers said more data is still needed on how long single-dose protection lasts, particularly in males and for HPV-related diseases beyond cervical cancer.
“The data show how important HPV vaccination is to prevent persistent HPV infections that lead to cancer,” said Ulrich.
“The review also contributes to the body of evidence supporting a one-dose regimen, while acknowledging where more data are still needed, especially about its long-term durability and effectiveness in preventing certain types of cancer, especially in men.”
The results strengthen confidence in HPV vaccination programs worldwide and suggest that simpler single-dose schedules could make vaccination campaigns cheaper, easier to deliver and more accessible, particularly in lower-income countries where cervical cancer deaths remain highest.
More from Linda Geddes
